Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
Laurent Peyrin‐Biroulet(Délégation Centre-Est), Peter Bossuyt(Imelda Hospital), Mauro Bafutto, Kamran Ayub, Michael Blaeker, Astrid Scalori(Roche (United Kingdom)), V. R. Bohman, Irit Avni‐Biron, Ailsa Hart(St Mark's Hospital), William J. Sandborn(University of San Diego), Laurent Beaugerie(Assistance Publique – Hôpitaux de Paris), Pascal Juillerat(University of Bern), Matthieu Allez(Inserm), Pradeep Bekal, Brian W. Behm, Swati Tole, M. Catherine Bennett(University of New Mexico), Curtis A. Baum, Edward V. Loftus(Mayo Clinic), Alessandro Armuzzi, Vibeke Andersen(Regionshospitalet Viborg), Young S. Oh(Memorial Hospital), Millie D. Long(University of North Carolina Health Care), Ashwin N. Ananthakrishnan(Harvard University), Dominik Bettenworth(University Hospital Münster), Charles Bernstein, Guy Aumais, Jennifer Pulley(Roche (United Kingdom)), Xavier Aldeguer Manté, Livia Biancone(University of Rome Tor Vergata), Akiko Chai, Stuart Bloom(Roche (United Kingdom)), Tariq Ali Ahmad, Elham Ostad-Saffari(Roche (United Kingdom)), Filip Baert(AZ Delta), Stuart R. Lacey(Roche (United Kingdom)), Peter Bossuyt(Imelda Hospital), Sudhir Bhaskar, Fernando Bermejo San José, George Bamias, Francisco Javier Bosques Padilla, I Altorjay, Evangelos Akriviadis, Jeffrey Axler, Bahri M. Bilir, Montserrat Andreu García, Humberto Aguilar, Isaac Bassan
Cited by 96
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k